Crestline Management LP cut its stake in Juno Therapeutics Inc (NASDAQ:JUNO) by 18.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,631,631 shares of the biopharmaceutical company’s stock after selling 1,717,168 shares during the quarter. Juno Therapeutics makes up 35.7% of Crestline Management LP’s portfolio, making the stock its biggest holding. Crestline Management LP owned 6.62% of Juno Therapeutics worth $348,841,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ark Investment Management LLC increased its position in Juno Therapeutics by 101.5% during the second quarter. Ark Investment Management LLC now owns 500,296 shares of the biopharmaceutical company’s stock worth $14,954,000 after buying an additional 252,029 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in Juno Therapeutics by 17.5% during the second quarter. Parametric Portfolio Associates LLC now owns 46,796 shares of the biopharmaceutical company’s stock worth $1,399,000 after buying an additional 6,970 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Juno Therapeutics during the second quarter worth $5,634,000. The Manufacturers Life Insurance Company boosted its holdings in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the period. Finally, Aperio Group LLC boosted its holdings in Juno Therapeutics by 4.2% during the third quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 1,194 shares during the period. 70.19% of the stock is currently owned by institutional investors and hedge funds.
Juno Therapeutics Inc (NASDAQ:JUNO) remained flat at $$86.96 during midday trading on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.61 and a quick ratio of 4.77. Juno Therapeutics Inc has a twelve month low of $19.62 and a twelve month high of $87.01. The stock has a market capitalization of $9,930.00, a P/E ratio of -16.16 and a beta of 3.24.
A number of equities research analysts have issued reports on JUNO shares. BidaskClub cut shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Zacks Investment Research cut shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 17th. Maxim Group set a $56.00 price target on shares of Juno Therapeutics and gave the company a “buy” rating in a report on Wednesday, December 13th. Citigroup cut shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 17th. Finally, Guggenheim cut shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, January 22nd. One research analyst has rated the stock with a sell rating, eighteen have issued a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $52.55.
ILLEGAL ACTIVITY NOTICE: “Juno Therapeutics Inc (JUNO) Shares Sold by Crestline Management LP” was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/03/14/juno-therapeutics-inc-juno-shares-sold-by-crestline-management-lp.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.